0001104659-22-121511.txt : 20221123 0001104659-22-121511.hdr.sgml : 20221123 20221123090734 ACCESSION NUMBER: 0001104659-22-121511 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221122 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221123 DATE AS OF CHANGE: 20221123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: uniQure N.V. CENTRAL INDEX KEY: 0001590560 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36294 FILM NUMBER: 221412424 BUSINESS ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP BUSINESS PHONE: 1-339-970-7000 MAIL ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP FORMER COMPANY: FORMER CONFORMED NAME: uniQure B.V. DATE OF NAME CHANGE: 20131030 8-K 1 tm2231226d1_8k.htm FORM 8-K
0001590560 false 00-0000000 0001590560 2022-11-22 2022-11-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):   November 22, 2022

 

uniQure N.V.

(Exact Name of Registrant as Specified in Charter)

 

The Netherlands   001-36294   N/A
(State or Other
Jurisdiction of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

Paasheuvelweg 25a,
1105 BP Amsterdam, The Netherlands		   N/A
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: +31-20-566-7394

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbol(s)   Name of each exchange on which registered:

Ordinary Shares, par value €0.05 per share

   QURE   The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 8.01Other Events.

 

On November 22, 2022, uniQure N.V. issued a press release announcing the approval by the U.S. Food and Drug Administration of HEMGENIX (etranacogene dezaparvovec). A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01Financial Statements and Exhibits.

 

(d)       Exhibit

 

Exhibit No. Description
99.1 Press Release of uniQure N.V. dated November 22, 2022 the approval by the U.S. Food and Drug Administration of HEMGENIX (etranacogene dezaparvovec).
   
104 Cover Page Interactive Data File (embedded with the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  UNIQURE N.V.
   
Date: November 23, 2022 By: /S/ DAVID J. CERVENY
    David J. Cerveny
    Chief Legal Officer

 

 

 

 EX-99.1 2 tm2231226d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

uniQure announces FDA approval of first gene therapy for adults with hemophilia B

 

~ Historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or
eliminates the need for prophylactic therapy, and generates elevated and sustained factor IX levels ~

 

~ uniQure conducted the multi-year clinical development program and will now leverage its leading gene
therapy manufacturing capabilities to supply CSL for commercialization ~

 

Lexington, MA and Amsterdam, the Netherlands, November 22, 2022 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that its partner, global biotechnology leader CSL (ASX: CSL), has received approval from the U.S. Food and Drug Administration (FDA) for HEMGENIX® (etranacogene dezaparvovec-drlb), a one-time gene therapy for the treatment of adults 18 years of age and older living with hemophilia B.

 

The product is approved for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy or have current or historical life-threatening hemorrhage or have repeated, serious spontaneous bleeding episodes. CSL licensed the exclusive global rights to HEMGENIX from uniQure in May 2021 and is now solely responsible for the further development, registration, and commercialization of the therapy.

 

“Today’s landmark approval represents a major milestone in the field of genomic medicine and ushers in a new treatment paradigm for patients living with hemophilia B,” said Matt Kapusta, chief executive officer of uniQure. “This is uniQure’s second internally-developed gene therapy to achieve approval and the world’s first gene therapy for hemophilia B, an historic achievement based on more than a decade of research and clinical development, as well as the tireless dedication of our employees, clinicians, patients and their families. For nearly 25 years, uniQure has been driven by a singular mission: to transform peoples’ lives by harnessing the power of gene therapy. This groundbreaking approval delivers on this promise by providing people with hemophilia B the possibility of being liberated from burdensome infusions and an ability to unlock the potential in their daily lives. We offer our sincere gratitude to the hemophilia community, without whose years of dedication and invaluable support this medical breakthrough could not have been achieved.”

 

Hemophilia B is a rare, lifelong bleeding disorder caused by a single gene defect, resulting in insufficient production of factor IX, a protein primarily produced by the liver that helps blood clots form. Treatments for moderate to severe hemophilia B include prophylactic infusions of factor IX replacement therapy to temporarily replace or supplement low levels of blood-clotting factor and, while these therapies are effective, those with hemophilia B must adhere to strict, lifelong infusion schedules. They may also still experience spontaneous bleeding episodes as well as limited mobility, joint damage or severe pain as a result of the disease. For appropriate patients, HEMGENIX allows people living with hemophilia B to produce their own factor IX, which can lower the risk of bleeding.

 

In the ongoing clinical trial, HEMGENIX reduced the rate of annual bleeds and 94 percent of patients discontinued factor IX prophylaxis and remained prophylaxis-free.

 

 

 

 

uniQure conducted the research and clinical development for the product, which included three clinical trials across 34 global sites and involving 67 adults with hemophilia B. In May 2021, uniQure and CSL completed a licensing transaction providing CSL Behring with exclusive rights to commercialize and continue clinical development of HEMGENIX globally. uniQure is responsible for the global manufacturing of the product at its licensed Lexington, MA facility. Under the terms of the agreement, uniQure has received payments from CSL totaling approximately $500 million and is eligible to receive up to an additional $1.5 billion in commercial milestone payments and tiered, double-digit royalties in a range up to a low-twenties percentage of net product sales arising from the collaboration.

 

“CSL is proud to have been at the forefront of providing life-changing medicines for rare diseases for over a century. HEMGENIX, originally developed by our uniQure colleagues, is just such a medicine. Today’s historic approval builds on CSL’s promise to put patients first in all that we do to discover, develop and deliver biotherapeutics and vaccines that meet their needs,” said Dr. Bill Mezzanotte, head of research & development and chief medical officer of CSL. “With HEMGENIX, CSL now offers people living with Hemophilia B another remarkable option for better and more durable control over their disease.”

 

“We are thrilled to witness this milestone in hemophilia B treatment,” shared Kim Phelan, chief operating officer of the Coalition for Hemophilia B. “Over the years we have seen a variety of advancements for the hemophilia community, but gene therapy is the first treatment option to offer those living with hemophilia B and caregivers the possibility of freedom from the need for regular, ongoing infusions.”

 

The FDA approval is supported by results from the pivotal HOPE-B trial, the largest gene therapy trial in hemophilia B to date. Results from the study demonstrated that HEMGENIX allowed patients to produce mean factor IX activity of 39 percent at six months and 36.7 percent at 24 months post infusion. Seven to 18 months post-infusion, the mean adjusted annualized bleeding rate (ABR) for all bleeds was reduced by 54 percent compared to the six-month lead-in period on factor IX prophylactic replacement therapy (4.1 to 1.9). In addition, 94 percent (51 out of 54) of patients treated with HEMGENIX discontinued use of prophylaxis and remained free of previous continuous routine prophylaxis therapy. The most common side effects (incidence ≥5%) were liver enzyme elevations, headache, elevated levels of a certain blood enzyme, flu-like symptoms, infusion-related reactions, fatigue, nausea and feeling unwell.

 

“HEMGENIX is unique in its approach to increase mean factor IX activity and hemostatic protection in those with hemophilia B, and today’s approval could fundamentally transform the treatment paradigm for this life-long condition,” said Dr. Steven Pipe, professor and the Laurence A. Boxer Research professor of pediatrics and professor of pathology at the University of Michigan and a lead investigator in the HOPE-B study. “As a clinician, I look forward to being able to provide a new treatment option that may help patients treated with HEMGENIX become free from the regular infusion schedule that many people living with hemophilia B rely on to protect them from the debilitating effects of the condition.”

 

HEMGENIX is currently under assessment by other regulatory agencies. Product information on HEMGENIX, including its prescribing information, will be provided by CSL Behring.

 

About Hemophilia B

 

Hemophilia B is a life-threatening rare disease. People with the condition are particularly vulnerable to bleeds in their joints, muscles, and internal organs, leading to pain, swelling, and joint damage. Current treatments for moderate to severe hemophilia B include life-long prophylactic infusions of factor IX to temporarily replace or supplement low levels of the blood-clotting factor.

 

 

 

 

About HEMGENIX

 

HEMGENIX is a gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX, the deficient protein in hemophilia B. It uses AAV5, a non-infectious viral vector, called an adeno-associated virus (AAV). The AAV5 vector carries the Padua gene variant of Factor IX (FIX-Padua) to the target cells in the liver, generating factor IX proteins that are 5x-8x more active than normal. These genetic instructions remain in the target cells, but generally do not become a part of a person’s own DNA. Once delivered, the new genetic instructions allow the cellular machinery to produce stable levels of factor IX.

 

About the Pivotal HOPE-B Trial

 

The pivotal Phase III HOPE-B trial is an ongoing, multinational, open-label, single-arm study to evaluate the safety and efficacy of HEMGENIX. Fifty-four adult hemophilia B patients classified as having moderately severe to severe hemophilia B and requiring prophylactic factor IX replacement therapy were enrolled in a prospective, six-month or longer observational period during which time they continued to use their current standard of care therapy to establish a baseline Annual Bleeding Rate (ABR). After the six-month lead-in period, patients received a single intravenous administration of HEMGENIX at the 2x10^13 gc/kg dose. Patients were not excluded from the trial based on pre-existing neutralizing antibodies (NAbs) to AAV5.

 

A total of 54 patients received a single dose of HEMGENIX in the pivotal trial, with 53 patients completing at least 18 months of follow-up. The primary endpoint in the pivotal HOPE-B study was ABR 52 weeks after achievement of stable factor IX expression (months 7 to 18) compared with the six-month lead-in period. For this endpoint, ABR was measured from month seven to month 18 after infusion, ensuring the observation period represented a steady-state factor IX transgene expression. Secondary endpoints included assessment of factor IX activity.

 

No serious adverse reactions were reported. One death resulting from urosepsis and cardiogenic shock in a 77-year-old patient at 65 weeks following dosing was considered unrelated to treatment by investigators and the company sponsor. A serious adverse event of hepatocellular carcinoma was determined to be unrelated to treatment with HEMGENIX by independent molecular tumor characterization and vector integration analysis. No inhibitors to factor IX were reported.

 

Important Safety Information (ISI)

 

What is HEMGENIX?

 

HEMGENIX®, etranacogene dezaparvovec-drlb, is a one-time gene therapy for the treatment of adults with hemophilia B who:

 

●Currently use Factor IX prophylaxis therapy, or

●Have current or historical life-threatening bleeding, or

●Have repeated, serious spontaneous bleeding episodes.

 

HEMGENIX is administered as a single intravenous infusion and can be administered only once.

 

What medical testing can I expect to be given before and after administration of HEMGENIX?

 

To determine your eligibility to receive HEMGENIX, you will be tested for Factor IX inhibitors. If this test result is positive, a retest will be performed 2 weeks later. If both tests are positive for Factor IX inhibitors, your doctor will not administer HEMGENIX to you. If, after administration of HEMGENIX, increased Factor IX activity is not achieved, or bleeding is not controlled, a post-dose test for Factor IX inhibitors will be performed.

 

 

 

 

HEMGENIX may lead to elevations of liver enzymes in the blood; therefore, ultrasound and other testing will be performed to check on liver health before HEMGENIX can be administered. Following administration of HEMGENIX, your doctor will monitor your liver enzyme levels weekly for at least 3 months. If you have preexisting risk factors for liver cancer, regular liver health testing will continue for 5 years post-administration. Treatment for elevated liver enzymes could include corticosteroids.

 

What were the most common side effects of HEMGENIX in clinical trials?

 

In clinical trials for HEMGENIX, the most common side effects reported in more than 5% of patients were liver enzyme elevations, headache, elevated levels of a certain blood enzyme, flu-like symptoms, infusion-related reactions, fatigue, nausea, and feeling unwell. These are not the only side effects possible. Tell your healthcare provider about any side effect you may experience.

 

What should I watch for during infusion with HEMGENIX?

 

Your doctor will monitor you for infusion-related reactions during administration of HEMGENIX, as well as for at least 3 hours after the infusion is complete. Symptoms may include chest tightness, headaches, abdominal pain, lightheadedness, flu-like symptoms, shivering, flushing, rash, and elevated blood pressure. If an infusion-related reaction occurs, the doctor may slow or stop the HEMGENIX infusion, resuming at a lower infusion rate once symptoms resolve.

 

What should I avoid after receiving HEMGENIX?

 

Small amounts of HEMGENIX may be present in your blood, semen, and other excreted/secreted materials, and it is not known how long this continues. You should not donate blood, organs, tissues, or cells for transplantation after receiving HEMGENIX.

 

Please see full prescribing information for HEMGENIX.

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

 

You can also report side effects to CSL Behring’s Pharmacovigilance Department at 1-866-915-6958.

 

About uniQure

 

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other diseases. www.uniQure.com

 

 

 

 

uniQure Forward-Looking Statements

 

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," “establish,” "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," “seek,” "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements about whether we are able to bring AMT-061 to people living with hemophilia B and whether the treatment will be transformational. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with the impact of the postponement in our clinical trial for Huntington’s disease, the impact of financial and geopolitical events on our Company and the wider economy and health care system, our Commercialization and License Agreement with CSL Behring, our clinical development activities, clinical results, collaboration arrangements, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company’s periodic securities filings, including its Annual Report on Form 10-K filed February 25, 2022. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

 

uniQure Contacts:    
     
FOR INVESTORS:   FOR MEDIA:
     
Maria E. Cantor Chiara Russo Tom Malone
Direct: 339-970-7536 Direct: 617-306-9137 Direct: 339-970-7558
Mobile: 617-680-9452 Mobile: 617-306-9137 Mobile:339-223-8541
m.cantor@uniQure.com c.russo@uniQure.com t.malone@uniQure.com

 

 

 

 EX-101.SCH 3 qure-20221122.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 qure-20221122_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 qure-20221122_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2231226d1_ex99-1omg001.jpg GRAPHIC begin 644 tm2231226d1_ex99-1omg001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Nov. 22, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 22, 2022
Entity File Number 001-36294
Entity Registrant Name uniQure N.V.
Entity Central Index Key 0001590560
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code P7
Entity Address, Address Line One Paasheuvelweg 25a
Entity Address, City or Town Amsterdam
Entity Address, Country NL
Entity Address, Postal Zip Code 1105 BP
City Area Code +31
Local Phone Number 20-566-7394
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary Shares, par value €0.05 per share
Trading Symbol QURE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2231226d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001590560 2022-11-22 2022-11-22 iso4217:USD shares iso4217:USD shares 0001590560 false 00-0000000 8-K 2022-11-22 uniQure N.V. P7 001-36294 Paasheuvelweg 25a 1105 BP Amsterdam NL +31 20-566-7394 false false false false Ordinary Shares, par value €0.05 per share QURE NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://uniqure.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2231226d1_8k.htm qure-20221122.xsd qure-20221122_lab.xml qure-20221122_pre.xml tm2231226d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2231226d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2231226d1_8k.htm" ] }, "labelLink": { "local": [ "qure-20221122_lab.xml" ] }, "presentationLink": { "local": [ "qure-20221122_pre.xml" ] }, "schema": { "local": [ "qure-20221122.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "qure", "nsuri": "http://uniqure.com/20221122", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2231226d1_8k.htm", "contextRef": "From2022-11-22to2022-11-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://uniqure.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2231226d1_8k.htm", "contextRef": "From2022-11-22to2022-11-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-121511-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-121511-xbrl.zip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

H4&X$S MI3>UY4E3HR<5]H<\JE"_4!Q75&1\PLR(U%HHQG2E%C.JDC3FC ^;#L_YQ(\B MH:JL';=DZR0S"/@XHK[$GBP]QSX=&^H%M6;Q4YCYQGS\J)%9E8AIIT8SN!+,[O=Z-M]OVULV/8Q] M^$RM@7Q@SP'U^(E,6PU\R!%2R+(C&*6_ .GB:Z8-28, M8&2P8 [7!:N(JYR?(:.8VU1$P26V+J*][6GB30J$?%PS(H/T)C6L0R 9 10N M:?:VBA" I>#;IV(U_Z<8*U9_36;J! D#R6,JB4H2\!CIS:K94[K4 O) MS:Y/2%B&-0&P#,^L 5HH*HYA@(,5#J5/O$5P4B_$]"%/O9L21MA_L]!.-': MC-A(R0_!TD"+>7)!KEB]>G?RLO_MVVHDGQPC.CC8RS)G1C>124;1UX9BZO1>R)]C'(KF" M[O0,7D1B@(Y ME4/H%M<)/*=Y]X?/3Z5>1B[ I7J7' AYU$7M/ IA@Q01 MGY ;*H0PBKN:"3*PTD!0 H_N/QIL\I8&>P\XMO4Q4J^1^>P!'FWLHRV0?$>"YA@729/&$ M.IK")_HVA@9TI+L=&$=J9W#0EPS04^.TZJ?)!W!E,9LCD<- 7BCZ.2PM#0,R M16Z2,69#O-%3&2%YFHDQ-H9CW"HC3.=NAGN!^U+S0'K."&3I*HN@*T2--"K* MR3-?J[)$#[(91:E);AF:E.2)46N/OZT4-T@YFE%:,&T"(X^K+-8D_10/-FKP M2_7@5LF(O2Q'HXSA498JZK$25)V5;!Y.DCD8BWG'<-("+/+XKS5B31+%(>(O M>P7I.W7!%HNV>YJ4 $9"$W8H2M+^3F/W7,YW\?/[C#V9LW-OD G$RW9D#0C M4%8+PXQ/B$L,+W4? MK93#98ET\V7(W.:6*$B,X.:*A M&PX^-NS])?[QIL..!?(._+Z;/KZID(T"/2?FND#Z5$CY#Q0BDTIH)%$83P*I3WR'0.8Z5JA\D#5"?,%<.":B/A0$#E&.F$IB)/]*3YJ;1L8+#KNX M!@9RBVT>MQ,-1^0!7ZWT&7[-.?RZO^*X:^6B580I&*M::KIH9MF#;N>D4:QL M*0;G)]1ZE$2DJQ"OBRJE5D!G)5QD$\J-7); 4F=5$:6FZ#GH32KAR-7;5A#=^FEQ+/=6W/TL(VRL@?I74R!L/D0>/K M.S+@J$P&B^:[0D8V7@@X[_.4NE[>+'!*?-&HOE.)?06J0=Y54HY4J.'PQQTJ MQF?(&V!^..A%#G21Y%CRA:%Q>RK2# 5QEFDRVXQ./W,2 M1_5\\W>CGBZY)VW7H9+D)G:N^D^N!+?C6%]:C;H=X0FON)!>!K&_19E+MT+A M@>2%9*IV H$R=R/083%I S[G!.C<68-Q MWD"P3J:4?QX?'[>P+#8EF0?X( C&?PLC3=]C?11<"NP MWG!G4VD$H-%CXW)90ZBJCA;-VMP +F-<+OIC*D5PM;%M\1\4W!T!^D MZSG7)2(!P4//CV'E2HHII:S4O)A2)^A0VB:>>]-^&G"V@1J.2X=37P><-3H0 MZT9XWU^%:#/72._)&NMVXWN#IUB-Z,W6U>;&_VQNJTGT\,,$%HGZ:DY"5S\1 MEDP4EWMCW\TG( 1)8>C&1";5-U>8BG:3F0I3ILE'SL%!.C@A,N?WWPY'!1MI M,O:WV+:LT\FA%'<%5[R) 41#]N"UV\]:F+0#H]EW[VPWU$<*\DRTDEA>E W\ MELRR)8/>K^;B,:7_C?Q]/.L1>0?E9Z FPA8&IG"VPU'R <+&?-WEI, MX5Q!K6_FBI)DAC3NNY4\%F#Y00WTAESK.HE%6G;D(2J_W!XOAY8UPU:KW$N7 MO%]X!%M^!1UDO36";;)"M)6[EVIM]KH<>K6%.246M.@33D>X39TC$;3&P46] M4\+/*6ML$K>HVS4:<$0KW?*@X!T3[+6P@G%")UY@NXLIM?2R57[\F$^7]6T:"B,DZKL[3B1% MP+F#U'*' 4E'1!T@,<4[JLH\1$W@;(WC(>AM@H>A,3N<9^(V$N2P:KBR5Y(S M9N348$DV1$K80I1DH"@O(C;4&<(E $87ZZ5P_T:]E"6PD!86&SCCF+ZO M3X:'A\=O?_C+O8U[_/O9R?"%_]U->IG$Y91FW?CNZQ_4/3_UT\!2E=3'XGF& M%^G.@H/SPZ6%;._RFP_/#Y^M?DGGY*D MK?[>&]_^9FU(O&B=5+N:%W7KKN1 MX3/_"^>P;2X+>'A^2O]'-/_J*. ?G*PY^>KS#S%^&4<].O4'2_\E+/V\PZ5? MQM)P$O5WX^=7]\4MA-4EO1PQ\O&1-9EQJ--*M)I1NU[[39MQ-38RMSV2^DDZ M*:71L322@M-)E6,^GT-59(Y8)W+@D&L,4G:GA*K;N1XD^,;AS')J\ANNKSFW M=<2N%GR4DY'S<-#0-US7E6$\Y%)[O3KP'JCCL22S]* _GI1P MDU4B9Z_HT!)_&4K))J< %Z/Z!)S2AYR'@FF9\E!\A*O;\<-;"JV_)6[ MBJ-L"'"=@F"S>):FZ?F4_UJ&AT+AWT]&XH$34',0]2H3HAAX\ M4ATNQ2 'XO:Z4&SB"OH^A[M,ZIZ"@PY:H.[ASWUGK51E#%;FK ="BH M= !.C4YA)9S]#BLC0[_DNAAL\T#*3N-D2&*W4W6GF( M\[H2C%E'7]6%WJ,IJRA+@J7\@!6ICMW=>+O]]@UGG_R])& MG6$>\'>TNH5#$EK65D M_B-_H)+G@J"A045MKC MN?3#%^(30*"1'*GGNQ3<)H@O"/@N[IBBZ0MX42<%DF?1EO]]].ML1N=@] S!W)*; M)3G@KF&N.W+W%!M9EC&":!"8]!KQG[F**$N,'Q9&?E!T8)A=F>LV+7U:]2&C M)J I]6I:KGDFX>P)-3Y#YST#Z.G8THV8;EZZBDQZ5(B%AYRFWBG%_'LB[V7^RL=''6_W-C2=/;K5P$*TH4>*K M:QR)6I0!"1KM_:'O[F2J(3$1PJ))DE*RTNT<&NK2F[G*-6BPN]O?V]SI[^[M MW&X:A&ZY<#?H[9?X&Z_A2 K?"=RQ4KYKC%3-W73+TU7JO5J5V3[)/R9P;POSM%7*7D2FI\Z11*'5WY/*BE^Y<;1\L>U611Z K M+OY<^",1%':,_0'3G<7<+J-U@7L1W+2K__:6K[/\(S:NEB=;W?7R-KK M]8Z?G8NGCG*IPY?*']I?F0F6W"%(_A(.Y\I6$ M[\N34P+?'O"2'G.?\+7UR2PA-U3W+\HMI-8U?5BR,>O M"1R0W/+W!Y:VU]H6!S>74[XGG>ZHH>?#T3Z.$89OSOL;NWR)P*?.XC() M_&#M#B4/UC]1QDM&]\NYJX F88.G6%AJ.^S#Y M5B*:Q9%1CE#R%<*,3%);KIWY8_=<)V#HLE@4H$;/O[IT134]_5HN 5-#?Z>7 M;+H1]??:VVO?*"05T*2^";CF::]]_17DCN_6$;"W=7\S@\V-_E_I#2SGR(SRB@+>K1WY0P8#]0.W*HC@R_;H^KH;]R<%_ 8$ M(D==L=>* GEH-07=UH]ZD_/S(O?"_S$$LH2&8)ANQ\)%3;2_RJ>:Q^X,S2>& MY&;V9,Q'M9I65(Y^%0UKZB\1KTJ*L7_?/WE1=U,UNZ>6NZN^>-)6WY6+D%E% MY@5B6?_3/0Y!;^BCDK#VGH]45]NIMK];U[3*-W$OGGYJD3?]>9\7%'M%9?&T M]==YS@^O7\JC[VKBWO3<=OLY[JWZ4C*LG>B3'_ZZJ;XJ>8_>G:KCMS^^/#M_ M=WIV/6W7;^6KK^3-R\/CX(KM[HU&;FZS#\ZRWN,,GAZ,DT[/7W'F_T'^]L[_[>!/%S[FX^ M[F]O$'ZY_?A;S5GO<^?);>+#&[J-W A-=I]L]/<>[6S]WC1ISOFM^.#F)#9L M;6WWG^P\VKQ-;*!K?0<16Z/_7@$:?V'-D4$L! A0#% @ \$AW5>1]4/G_"@ M;(< !4 ( !: , '%U' D70 !8 ( !,R@ '1M,C(S G,3(R-F0Q7V5X.3DM,2YH=&U02P4& 4 !0!) 0 144 end